The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison
Summary What is known and objective Melanoma causes the majority of skin cancer‐related deaths. The outcome of melanoma depends on its stage at diagnosis. Currently, for patients with advanced melanoma, two MEK inhibitors (trametinib and cobimetinib) have been authorized by the European Medicines Ag...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2016-06, Vol.41 (3), p.285-289 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 289 |
|---|---|
| container_issue | 3 |
| container_start_page | 285 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 41 |
| creator | Galván-Banqueri, M. Ubago-Pérez, R. Molina-López, T. |
| description | Summary
What is known and objective
Melanoma causes the majority of skin cancer‐related deaths. The outcome of melanoma depends on its stage at diagnosis. Currently, for patients with advanced melanoma, two MEK inhibitors (trametinib and cobimetinib) have been authorized by the European Medicines Agency. The main objective of this study was to compare the relative efficacy of trametinib–dabrafenib and cobimetinib–vemurafenib in patients with advanced melanoma through adjusted indirect treatment comparisons (ITCs).
Methods
A search was made up to the 3rd of November 2015. Databases consulted were MEDLINE, the Cochrane Library and the Centre for Reviews and Dissemination. Randomized controlled trials (RCTs) which compared the efficacy of trametinib–dabrafenib or cobimetinib–vemurafenib versus a common treatment comparator, in which outcomes of overall survival, progression‐free survival (PFS) and overall response rate (ORR) were considered. ITCs were carried out using the method proposed by Bucher et al.
Results and discussion
Two RCTs were included (one for each drugs combination). The results of the adjusted ITCs showed that there were no statistically significant differences between the two combinations in terms of PFS and ORR.
What is new and conclusion
The ITCs indicate no difference in efficacy between both treatments. However, there should be an independent, head‐to‐head trial of both combinations to confirm the results. |
| doi_str_mv | 10.1111/jcpt.12390 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1827892926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4059151261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4640-3f2073fd5d497ede1e91ceca5504e9f813adc58f4f165c8ab7841cfb59f5f8203</originalsourceid><addsrcrecordid>eNqFkTuPEzEUhS0EYsNCww9AI9EgpFn8HNt0KEAALY8iCERjeexr4TCPYM8E0vHTcchmCwpwcy2d7xxd-yB0n-ALUs6TjdtOF4QyjW-gBWGNqKkk-CZaYNromksqz9CdnDcY40ZSdhudUYmlplIt0K_1V6gSdHaKO6hcF4fobFdBCGW6fTWGakq2h6kIbe1tm2yAcq3s4Cs3tvEk7aCfT1ocKut3dnDgq75kD2NvnxZHEXxM4Kbi7Lc2xTwOd9GtYLsM967mOfr48sV6-aq-fL96vXx2WTvecFyzQLFkwQvPtQQPBDRx4KwQmIMOijDrnVCBB9IIp2wrFScutEIHERTF7Bw9OuZu0_h9hjyZPmYHXdkOxjkbosp_aKpp839UasxFyT-gD_9CN-OchvKQQinNlSSMFOrxkXJpzDlBMNsUe5v2hmBzqNAcKjR_Kizwg6vIue3BX6OnzgpAjsCP2MH-H1HmzfLD-hRaHz0xT_Dz2mPTN9NIJoX59G5lnqsvfP159dZQ9huiXrcv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1789487131</pqid></control><display><type>article</type><title>The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Galván-Banqueri, M. ; Ubago-Pérez, R. ; Molina-López, T.</creator><creatorcontrib>Galván-Banqueri, M. ; Ubago-Pérez, R. ; Molina-López, T.</creatorcontrib><description>Summary
What is known and objective
Melanoma causes the majority of skin cancer‐related deaths. The outcome of melanoma depends on its stage at diagnosis. Currently, for patients with advanced melanoma, two MEK inhibitors (trametinib and cobimetinib) have been authorized by the European Medicines Agency. The main objective of this study was to compare the relative efficacy of trametinib–dabrafenib and cobimetinib–vemurafenib in patients with advanced melanoma through adjusted indirect treatment comparisons (ITCs).
Methods
A search was made up to the 3rd of November 2015. Databases consulted were MEDLINE, the Cochrane Library and the Centre for Reviews and Dissemination. Randomized controlled trials (RCTs) which compared the efficacy of trametinib–dabrafenib or cobimetinib–vemurafenib versus a common treatment comparator, in which outcomes of overall survival, progression‐free survival (PFS) and overall response rate (ORR) were considered. ITCs were carried out using the method proposed by Bucher et al.
Results and discussion
Two RCTs were included (one for each drugs combination). The results of the adjusted ITCs showed that there were no statistically significant differences between the two combinations in terms of PFS and ORR.
What is new and conclusion
The ITCs indicate no difference in efficacy between both treatments. However, there should be an independent, head‐to‐head trial of both combinations to confirm the results.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.12390</identifier><identifier>PMID: 27079278</identifier><identifier>CODEN: JCPTED</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject><![CDATA[Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Azetidines - administration & dosage ; cobimetinib ; dabrafenib ; Disease-Free Survival ; Humans ; Imidazoles - administration & dosage ; indirect treatment comparison ; Indoles - administration & dosage ; melanoma ; Melanoma - drug therapy ; Melanoma - pathology ; Neoplasm Staging ; Oximes - administration & dosage ; Piperidines - administration & dosage ; Pyridones - administration & dosage ; Pyrimidinones - administration & dosage ; Randomized Controlled Trials as Topic ; Skin Neoplasms - drug therapy ; Skin Neoplasms - pathology ; Sulfonamides - administration & dosage ; Survival Rate ; trametinib ; Treatment Outcome ; vemurafenib]]></subject><ispartof>Journal of clinical pharmacy and therapeutics, 2016-06, Vol.41 (3), p.285-289</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><rights>Copyright © 2016 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4640-3f2073fd5d497ede1e91ceca5504e9f813adc58f4f165c8ab7841cfb59f5f8203</citedby><cites>FETCH-LOGICAL-c4640-3f2073fd5d497ede1e91ceca5504e9f813adc58f4f165c8ab7841cfb59f5f8203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.12390$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.12390$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27079278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galván-Banqueri, M.</creatorcontrib><creatorcontrib>Ubago-Pérez, R.</creatorcontrib><creatorcontrib>Molina-López, T.</creatorcontrib><title>The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description>Summary
What is known and objective
Melanoma causes the majority of skin cancer‐related deaths. The outcome of melanoma depends on its stage at diagnosis. Currently, for patients with advanced melanoma, two MEK inhibitors (trametinib and cobimetinib) have been authorized by the European Medicines Agency. The main objective of this study was to compare the relative efficacy of trametinib–dabrafenib and cobimetinib–vemurafenib in patients with advanced melanoma through adjusted indirect treatment comparisons (ITCs).
Methods
A search was made up to the 3rd of November 2015. Databases consulted were MEDLINE, the Cochrane Library and the Centre for Reviews and Dissemination. Randomized controlled trials (RCTs) which compared the efficacy of trametinib–dabrafenib or cobimetinib–vemurafenib versus a common treatment comparator, in which outcomes of overall survival, progression‐free survival (PFS) and overall response rate (ORR) were considered. ITCs were carried out using the method proposed by Bucher et al.
Results and discussion
Two RCTs were included (one for each drugs combination). The results of the adjusted ITCs showed that there were no statistically significant differences between the two combinations in terms of PFS and ORR.
What is new and conclusion
The ITCs indicate no difference in efficacy between both treatments. However, there should be an independent, head‐to‐head trial of both combinations to confirm the results.</description><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Azetidines - administration & dosage</subject><subject>cobimetinib</subject><subject>dabrafenib</subject><subject>Disease-Free Survival</subject><subject>Humans</subject><subject>Imidazoles - administration & dosage</subject><subject>indirect treatment comparison</subject><subject>Indoles - administration & dosage</subject><subject>melanoma</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - pathology</subject><subject>Neoplasm Staging</subject><subject>Oximes - administration & dosage</subject><subject>Piperidines - administration & dosage</subject><subject>Pyridones - administration & dosage</subject><subject>Pyrimidinones - administration & dosage</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - pathology</subject><subject>Sulfonamides - administration & dosage</subject><subject>Survival Rate</subject><subject>trametinib</subject><subject>Treatment Outcome</subject><subject>vemurafenib</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkTuPEzEUhS0EYsNCww9AI9EgpFn8HNt0KEAALY8iCERjeexr4TCPYM8E0vHTcchmCwpwcy2d7xxd-yB0n-ALUs6TjdtOF4QyjW-gBWGNqKkk-CZaYNromksqz9CdnDcY40ZSdhudUYmlplIt0K_1V6gSdHaKO6hcF4fobFdBCGW6fTWGakq2h6kIbe1tm2yAcq3s4Cs3tvEk7aCfT1ocKut3dnDgq75kD2NvnxZHEXxM4Kbi7Lc2xTwOd9GtYLsM967mOfr48sV6-aq-fL96vXx2WTvecFyzQLFkwQvPtQQPBDRx4KwQmIMOijDrnVCBB9IIp2wrFScutEIHERTF7Bw9OuZu0_h9hjyZPmYHXdkOxjkbosp_aKpp839UasxFyT-gD_9CN-OchvKQQinNlSSMFOrxkXJpzDlBMNsUe5v2hmBzqNAcKjR_Kizwg6vIue3BX6OnzgpAjsCP2MH-H1HmzfLD-hRaHz0xT_Dz2mPTN9NIJoX59G5lnqsvfP159dZQ9huiXrcv</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Galván-Banqueri, M.</creator><creator>Ubago-Pérez, R.</creator><creator>Molina-López, T.</creator><general>Blackwell Publishing Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>201606</creationdate><title>The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison</title><author>Galván-Banqueri, M. ; Ubago-Pérez, R. ; Molina-López, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4640-3f2073fd5d497ede1e91ceca5504e9f813adc58f4f165c8ab7841cfb59f5f8203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Azetidines - administration & dosage</topic><topic>cobimetinib</topic><topic>dabrafenib</topic><topic>Disease-Free Survival</topic><topic>Humans</topic><topic>Imidazoles - administration & dosage</topic><topic>indirect treatment comparison</topic><topic>Indoles - administration & dosage</topic><topic>melanoma</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - pathology</topic><topic>Neoplasm Staging</topic><topic>Oximes - administration & dosage</topic><topic>Piperidines - administration & dosage</topic><topic>Pyridones - administration & dosage</topic><topic>Pyrimidinones - administration & dosage</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - pathology</topic><topic>Sulfonamides - administration & dosage</topic><topic>Survival Rate</topic><topic>trametinib</topic><topic>Treatment Outcome</topic><topic>vemurafenib</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galván-Banqueri, M.</creatorcontrib><creatorcontrib>Ubago-Pérez, R.</creatorcontrib><creatorcontrib>Molina-López, T.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galván-Banqueri, M.</au><au>Ubago-Pérez, R.</au><au>Molina-López, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>2016-06</date><risdate>2016</risdate><volume>41</volume><issue>3</issue><spage>285</spage><epage>289</epage><pages>285-289</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><coden>JCPTED</coden><abstract>Summary
What is known and objective
Melanoma causes the majority of skin cancer‐related deaths. The outcome of melanoma depends on its stage at diagnosis. Currently, for patients with advanced melanoma, two MEK inhibitors (trametinib and cobimetinib) have been authorized by the European Medicines Agency. The main objective of this study was to compare the relative efficacy of trametinib–dabrafenib and cobimetinib–vemurafenib in patients with advanced melanoma through adjusted indirect treatment comparisons (ITCs).
Methods
A search was made up to the 3rd of November 2015. Databases consulted were MEDLINE, the Cochrane Library and the Centre for Reviews and Dissemination. Randomized controlled trials (RCTs) which compared the efficacy of trametinib–dabrafenib or cobimetinib–vemurafenib versus a common treatment comparator, in which outcomes of overall survival, progression‐free survival (PFS) and overall response rate (ORR) were considered. ITCs were carried out using the method proposed by Bucher et al.
Results and discussion
Two RCTs were included (one for each drugs combination). The results of the adjusted ITCs showed that there were no statistically significant differences between the two combinations in terms of PFS and ORR.
What is new and conclusion
The ITCs indicate no difference in efficacy between both treatments. However, there should be an independent, head‐to‐head trial of both combinations to confirm the results.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>27079278</pmid><doi>10.1111/jcpt.12390</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2016-06, Vol.41 (3), p.285-289 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1827892926 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Azetidines - administration & dosage cobimetinib dabrafenib Disease-Free Survival Humans Imidazoles - administration & dosage indirect treatment comparison Indoles - administration & dosage melanoma Melanoma - drug therapy Melanoma - pathology Neoplasm Staging Oximes - administration & dosage Piperidines - administration & dosage Pyridones - administration & dosage Pyrimidinones - administration & dosage Randomized Controlled Trials as Topic Skin Neoplasms - drug therapy Skin Neoplasms - pathology Sulfonamides - administration & dosage Survival Rate trametinib Treatment Outcome vemurafenib |
| title | The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T19%3A19%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20relative%20clinical%20efficacy%20of%20trametinib-dabrafenib%20and%20cobimetinib-vemurafenib%20in%20advanced%20melanoma:%20an%20indirect%20comparison&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Galv%C3%A1n-Banqueri,%20M.&rft.date=2016-06&rft.volume=41&rft.issue=3&rft.spage=285&rft.epage=289&rft.pages=285-289&rft.issn=0269-4727&rft.eissn=1365-2710&rft.coden=JCPTED&rft_id=info:doi/10.1111/jcpt.12390&rft_dat=%3Cproquest_cross%3E4059151261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1789487131&rft_id=info:pmid/27079278&rfr_iscdi=true |